Nasdaq: $28.36 (+0.24) | AIM: £3.86 (-0.26)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 28 Sep 2017

CSCO 2017: Theliatinib Phase I Results

Novel EGFR TKI Theliatinib: An Open Label, Dose Escalation Phase I Clinical Trial

Lin Shen, Li Zhang, Hongyun Zhao, Wenfeng Fang, Jifang Gong

Venue: Chinese Society of Clinical Oncology Annual Meeting
Session: Esophageal Cancer
Presenter: Jifang Gong
Date: Thursday, September 28, 2017